#United States #New York #Class Action #Pomerantz Law Firm #Regeneron Pharmaceuticals

Investor Alert: Regeneron Pharmaceuticals Under Legal Scrutiny

Pomerantz LLP, a prominent law firm known for its advocacy in securities fraud litigation, has issued an alert to investors who have experienced losses in their holdings of Regeneron Pharmaceuticals, Inc. This communication serves to remind affected investors of an ongoing class action lawsuit against the company, highlighting crucial upcoming deadlines that may affect their legal rights.

Background of the Case

On April 29, 2026, during its first quarter earnings call, Regeneron revealed crucial updates about its Phase III Fianlimab-Libtayo Study. The announcement indicated that the eligibility criteria for patients undergoing progression-free survival analysis had been changed, which raised concerns among investors. Following this disclosure, Regeneron’s stock suffered a significant drop of 6.21%, closing at $686.36 a share on the same day.

Just weeks later, on May 15, 2026, the company publicly admitted that the Phase 3 Trial of Fianlimab failed to achieve statistical significance for its primary endpoint, a finding that further unsettled shareholders. This revelation resulted in an even sharper fall in the company's stock price, with shares plummeting by 9.82%, to a closing price of $629.68 on May 16.

Class Action Overview

The class action lawsuit aims to hold Regeneron, along with specific executives and directors, accountable for alleged securities fraud or unlawful business practices stemming from these events. Investors who acquired securities during the class period, which lasted through the announcements, are urged to consider joining the action.

Danielle Peyton, a representative from Pomerantz, invites investors who wish to serve as Lead Plaintiffs to express their interest before the September 14, 2026, deadline. Interested parties should reach out via email or phone, ensuring to include essential contact information and details of the number of shares held. A detailed complaint file is available for review at Pomerantz Law Firm’s website.

About Pomerantz Law Firm

With a legacy of over 85 years, Pomerantz LLP has established itself as a leader in corporate, securities, and antitrust class actions. Established by Abraham L. Pomerantz, often regarded as the founder of class action law, the firm has successfully represented numerous investors in seeking redress for breaches of fiduciary duty, corporate misconduct, and securities fraud.

The firm maintains offices in major cities worldwide, including New York, London, and Tel Aviv, and continues to be recognized for recovering substantial damages for its clients. This reputation underscores Pomerantz’s commitment to fighting for the rights of investors who have been adversely affected by unethical corporate practices.

Final Thoughts

For investors looking to protect their interests following the alarming updates from Regeneron Pharmaceuticals, now is the moment to act. As highlighted by Pomerantz, the opportunity to potentially join this class action—and have a say in its proceedings—comes with an approaching deadline. Thus, those impacted by the recent revelations are encouraged to take immediate action to ensure their rights and recover potential losses they may have incurred.

For further information or to inquire about the class action details, contact Pomerantz LLP at the provided email or phone number. Remember, timely action can be pivotal in matters of securities litigation.